B Cells Modulate Systemic Responses to *Pneumocystis murina* Lung Infection and Protect On-Demand Hematopoiesis via T Cell-Independent Innate Mechanisms when Type I Interferon Signaling Is Absent

Teri R. Hoyt, Erin Dobrinen, Irina Kochetkova, Nicole Meissner
Department of Microbiology and Immunology, Montana State University, Bozeman, Montana, USA

HIV infection results in a complex immunodeficiency due to loss of CD4+ T cells, impaired type I interferon (IFN) responses, and B cell dysfunctions causing susceptibility to opportunistic infections such as *Pneumocystis murina* pneumonia and unexplained comorbidities, including bone marrow dysfunctions. Type I IFNs and B cells critically contribute to immunity to *Pneumocystis* lung infection. We recently also identified B cells as supporters of on-demand hematopoiesis following *Pneumocystis* infection that would otherwise be hampered due to systemic immune effects initiated in the context of a defective type I IFN system. While studying the role of type I IFNs in immunity to *Pneumocystis* infection, we discovered that mice lacking both lymphocytes and type I IFN receptor (IFNAR−/−) developed progressive bone marrow failure following infection, while lymphocyte-competent type I IFN receptor-deficient mice (IFNAR−/−) showed transient bone marrow depression and extramedullary hematopoiesis. Lymphocyte reconstitution of lymphocyte-deficient IFNAR−/− mice pointed to B cells as a key player in bone marrow protection. Here we define how B cells protect on-demand hematopoiesis following *Pneumocystis* lung infection in our model. We demonstrate that adoptive transfer of B cells into IFNAR−/− mice protects early hematopoietic progenitor activity during systemic responses to *Pneumocystis* infection, thus promoting replenishment of depleted bone marrow cells. This activity is independent of CD4+ T cell help and B cell receptor specificity and does not require B cell migration to bone marrow. Furthermore, we show that B cells protect on-demand hematopoiesis in part by induction of interleukin-10 (IL-10)- and IL-27-mediated mechanisms. Thus, our data demonstrate an important immune modulatory role of B cells during *Pneumocystis* lung infection that complement the modulatory role of type I IFNs to prevent systemic complications.

*Pneumocystis* is a ubiquitous extracellular pulmonary fungal pathogen with strict species specificity. It is likely contracted via airborne transmission from often transiently infected individuals and commonly causes few or unspecific symptoms in otherwise healthy individuals leading to immunity (reviewed in references 1 and 2). However, *Pneumocystis* can cause severe and progressive interstitial pneumonia in patients with impaired acquired immunity with mortality rates up to 60% (3). While the total number of functional CD4+ T cells critically determines increased susceptibility to *Pneumocystis* lung infection, patients with B cell defects are also at risk. In this regard, *Pneumocystis* pneumonia (PCP) is an AIDS-defining condition during HIV disease progression and commonly occurs when CD4+ T cell counts drop below 200 cells/μL (4). Furthermore, immune suppressive and cell ablative therapy following solid-organ transplantation, autoimmunity, or cancer treatment reduce CD4+ T cell and/or B cell numbers and impair functions in non-HIV patients (reviewed in references 5 and 6). Drug regimens that predispose to severe *Pneumocystis* infections include high-dose glucocorticoid and B cell ablative treatments with rituximab (7–11). In addition, low-grade *Pneumocystis* infection is found in patients with potentially subtle immune suppressions such as young infants, HIV-positive patients receiving HAART (highly active antiretroviral therapy), or patients receiving low-dose and inhaled glucocorticoids (12–14). This can promote bronchial hyperreactivity, is associated with sudden infant death syndrome (SIDS) and exacerbation of chronic obstructive lung diseases (15–19).

*Pneumocystis* colonization also intensifies signs of systemic inflammation (20, 21). Thus, *Pneumocystis* may act as a profound comorbidity factor that may also enhance secondary systemic disease manifestations associated with chronic pulmonary diseases and HIV infection such as osteoporosis or bone marrow dysfunctions (22–28).

Immunity to *Pneumocystis* requires the presence of functional CD4+ T cells to stimulate antigen-specific immune globulin production by B cells and macrophage-mediated phagocytosis (4, 29–38). In addition, early innate type I interferon (IFN) production modulates this response and accelerates B cell differentiation into plasma cells and thus promotes *Pneumocystis murina*-specific antibody production (39). However, B cells also provide important T cell- and type I IFN-independent functions critical for the induction of immunity to *Pneumocystis*. One of these functions is...
the production of naturally occurring IgM antibodies against common fungal antigens that aid in *Pneumocystis* clearance (40). In addition, B cell-derived tumor necrosis factor alpha (TNF-α) production has been identified as a critical innate and antibody-independent mechanism to facilitate proper CD4⁺ T cell priming during responses to *Pneumocystis* lung infection (41, 42). While these B cell-mediated functions pertain to localized pulmonary responses and induction of pathogen clearance, we found that B cells also have important immune modulatory functions relevant to maintaining tissue homeostasis at distant organ sites to prevent immunity-driven tissue damage following systemic responses to *Pneumocystis* lung infection.

Both lymphocyte functions and type I IFN responses can be impaired as the result of HIV infection and immune suppressive treatment with, e.g., glucocorticoids (43–49). While studying the independent roles of both type I IFNs and lymphocytes in generating immunity to *Pneumocystis* lung infection, we recently discovered by serendipity that both type I IFN signaling and B cells are critical in regulating not only local but also systemic immune responses to *Pneumocystis* lung infection, and in this way, they protect on-demand hematopoiesis following the systemic inflammatory stress responses. We found that mice lacking both lymphocytes and type I IFN receptor (IFrag⁻/⁻) developed rapidly progressive bone marrow failure following pulmonary infection with *Pneumocystis* within 16 days, while lymphocyte-competent but type I IFN receptor-deficient mice (IFNAR⁻/⁻) show a transient bone marrow crisis with bone marrow depression and extramedullary hematopoiesis. These systemic symptoms occur without evidence for systemic dissemination of the pathogen and at a time when the pathogen lung burden is still low (50, 51). Immune reconstitution studies transferring splenocytes from either wild-type, IFNAR⁻/⁻, or B cell-deficient μMT mice into lymphocyte-deficient I Frag⁻/⁻ mice pointed to B cells as the key player in bone marrow protection (50).

Bone marrow dysfunctions in both lymphocyte-competent and lymphocyte-deficient type I IFN-deficient mice are associated with exuberant inflammasome-mediated immune activation with increased release of interleukin-1β (IL-1β) and IL-18 followed by excessive induction of downstream mediators such as gamma interferon (IFN-γ) and augmentation of TNF-α responses (51, 52). However, the mechanisms by which B cells modulate these effects and thus protect from bone marrow failure are still unclear.

Here we demonstrate that adoptive transfer of purified B cells into I Frag⁻/⁻ mice prior to infection protects early hematopoietic progenitor activity during systemic responses to *Pneumocystis* lung infection, thus promoting replenishment of depleted bone marrow cells. This activity does not require CD4⁺ T cell help, does not involve *Pneumocystis* clearance, and is mediated by innate, antigen-independent B cell functions. Transferred B cells predominantly migrate back to the spleen and lung, but not to bone marrow, suggesting a role of soluble factors in the role of B cell-mediated, systemic protection. Furthermore, we show that B cells complement the bone marrow protective activity of type I IFNs at least in part by induction of IL-10- and IL-27-mediated mechanisms possibly via interaction with and stimulation of macrophage/dendritic cells.

**MATERIALS AND METHODS**

Mice. All mice listed below were bred and maintained at Montana State University (MSU) Animal Resource Center. The mice were housed in ventilator cages and received sterile food and water. C.B17 SCID mice, as a source for *Pneumocystis murina* (PC) organism, and RAG1⁻/⁻ mice (C57BL/6 background) were initially purchased from Jackson Laboratory (catalog no. 001803 and 002096, respectively). I Frag⁻/⁻ mice were generated by crossing IFNARnull/null mice (C57BL/6 background) (kindly provided by E. Schmidt, MSU) with RAG1⁻/⁻ mice (C57BL/6 background) as previously described (50). Wild-type C57BL/6 mice were purchased from Charles River Laboratories (catalog no. 027), and IL-10⁻/⁻ mice were purchased from Jackson Laboratory (strain B6.129-IL10tm1wtsxg/J), B cell-deficient B6.129P2-Igh-μmice (μMT) mice were purchased from Jackson Laboratory (catalog no. 002438), and mice carrying B cells capable of expressing only a human transgenic B cell receptor specific to hen egg lysozyme (HEL) (C57BL/6-Tg[IghMD4]4Ccg/J) were crossed with B cell-deficient B6.129P2-Igh-μmice (μMT) mice to generate mice capable of producing only B cells with a B cell receptor (BCR) specific to HEL and kindly provided by F. Lund (53).

*Pneumocystis* lung infections. Experimental animals were intratracheally infected with 1 × 10⁶ *Pneumocystis murina* nuclei (herein referred to as *Pneumocystis*) in 100 μl of lung homogenate from infected source mice diluted in phosphate-buffered saline (PBS) buffer. *Pneumocystis* lung burden was assessed microscopically by enumeration of trophozoid and cyst nuclei in lung homogenates in 10 to 50 oil immersion fields as previously described (54). The limit of detection for this technique is log₈₀G.43.

Adoptive cell transfer and other treatments. Immune reconstitution studies of I Frag⁻/⁻ mice were performed using either total splenocytes derived from either wild-type C57BL/6 mice, B cell-deficient μMT mice, or B cell transgenic mice expressing a B cell receptor specific to hen egg lysozyme (HEL) (μMT mice). Donor animals were euthanized via CO₂ narcosis, and their spleens were removed aseptically. A single-cell suspension of spleen cells was prepared by homogenizing the spleens by forcing them through a mesh screen. The cell suspension was repeatedly filtered through 100-μm Nitex gauze to ensure that there were no clumps of cells. Animals were injected with 2 × 10⁶ to 3 × 10⁷ total cells in 200-μl volume of Hanks balanced salt solution (HBSS) solution via the tail vein 5 to 7 days prior to infection with *Pneumocystis* pathogen (50). For B cell transfer experiments, total spleen cells were isolated from wild-type C57BL/6 or IL-10⁻/⁻ mice. For these experiments, the spleens were steriley removed from donor mice and minced, and the cells were strained through a 100-μm mesh to make single-cell suspensions. Red blood cells were lysed using ACK lysis buffer (0.15 M NH₄Cl, 10.0 mM KHCO₃, 0.1 mM Na₂EDTA [pH 7.2]). Total cell numbers were determined by using a hemocytometer, and B cell isolation was performed via negative selection using a magnetically activated cell sorting (MACS) B cell isolation kit (Miltenyi Biotec) following the manufacturer’s protocol. The purity of isolated B cells was consistently >95%. The final cell concentrations were adjusted to 5 × 10⁷ B cells/ml in sterile PBS to be transferred into mice, and the mice received a total of 1 × 10⁷ B cells in 200 μl via tail vein injection.

For in vivo tracking, B cells isolated as described above were labeled with Vybrant CFDA/SE cell tracer following the manufacturer’s protocol (Invitrogen/Molecular Probes). Following the labeling procedure, 1 × 10⁷ wild-type B cells were injected into I Frag⁻/⁻ mice, and their spleens, lungs, and bone marrow were assessed for accumulation of transferred cells on days 1, 3, 5, and 7 postinfection. Cells could confidently be monitored to day 5 postinfection by fluorescence-activated cell sorting (FACS) using an LSR cell analyzer (Becton Dickinson [BD]). In a separate confirmation experiment, B cell migration patterns over the course of infection were monitored in spleen, lung, mediastinal lymph nodes, and bone marrow by detecting the cells using a mouse B cell-specific antibody stained with a marker cocktail as described below.

Some groups of I Frag⁻/⁻ mice received human recombinant IL-1 receptor antagonist (Kineret; Swedish Orphan Biovitrum) at a concentration of 25 mg/kg of body weight/day (55) over the course of infection,
while other groups were subcutaneously treated with 0.25 μg of recombinant, carrier-free IL-27 (Biolegend) every other day (56) or 0.4 μg of carrier-free IL-10 (57) over the course of Pneumocystis lung infection.

**Collection and differentiation of bone marrow (BM) and lung cells.**

BM cells from femurs and tibia were collected as previously described by flushing 2 ml of PBS through the BM canal using a 26.5-gauge needle and preparing a single-cell suspension (58).

BM cells were diluted 1:10 in PBS. The numbers of cells were determined, and the cells were spun onto glass slides and stained with Diff-Quik solution (Siemens). Cell differentiation was performed based on morphology and staining pattern to distinguish myeloid (including myeloblast-myelocyte and metamyelocyte stage), banded versus segmented neutrophils, eosinophils, and others (including erythroid, megakaryocytic, and lymphoid cells) (58).

FACS analysis was also applied to bone marrow cells as an additional unbiased measure of cell differentiation and for the detection and tracking of transferred B cells. Prior to FACS staining, red blood cell lysis of BM was performed using ACK lysis buffer. The cells were then suspended at 1 × 10^7/ml in FACS buffer (PBS containing 10% calf serum) containing Fc block transferred B cells. Prior to FACS staining, red blood cell lysis of BM was performed using ACK lysis buffer. FACS staining was performed as described above using the following antibody mix: anti-CD19 (phycoerythrin [PE]-Cy7, clone eBio1D3 eBioscience), anti-CD11b (Alexa Fluor 700, clone M1/70, BioLegend), anti-Ly-6G/6C (allophycocyanin [APC]-Cy7, clone RB6-8C5, Pharmingen) as previously described (52).

**RESULTS**

 **B cells provide T cell- and antigen-independent mechanisms to maintain hematopoiesis during systemic responses to Pneumocystis lung infection in type I IFN receptor-deficient mice.** As previously reported and shown in Fig. 1A, Pneumocystis lung infection causes a transient bone marrow depression in lymphocyte-competent IFNAR−/− mice and complete bone marrow failure in lymphocyte-deficient IFRag−/− mice within 16 days postinfection. Splenocyte transfer experiments into IFRag−/− mice suggested a specific bone marrow protective role of B cells in our system (50).

In these new studies, we set out to elucidate the mechanisms by which B cells act to protect from bone marrow failure following systemic immune responses to Pneumocystis lung infection in our model. To evaluate whether antigen-specific B cell receptor-mediated recognition of Pneumocystis is required for this bone marrow protective activity, IFRag−/− mice were immune reconstituted with total splenocytes isolated from either wild-type mice, B cell-deficient μMT mice, or HELμMT mice in which B cells are only capable to express a B cell receptor specific to hen egg lysozyme. The bone marrow responses of these mice were then determined at 16 days following Pneumocystis lung infection and compared to non-immune-reconstituted (unreconstituted) but infected IFRag−/− mice. As demonstrated in Fig. 1B, IFRag−/− mice that had received splenocytes containing B cells from either wild-type or HELμMT mice were protected from rapid bone marrow cell loss, while unreconstituted IFRag−/− mice as well as those receiving splenocytes deficient of B cells (μMT) were not protected. These data suggested that B cell-mediated activity relevant to protecting bone marrow functions are not antigen driven and may comprise as yet undefined innate B cell functions. However, IFRag−/− mice that had received wild-type splenocytes had significantly higher total bone marrow cell counts compared to those mice that had received splenocytes containing B cells with B cell receptor specificity to an irrelevant antigen (HEL). This is also reflected in lower percentages of mature and maturing neutrophils in bone marrow of IFRag−/− mice with transferred splenocytes from HELμMT mice, compared to mice with transferred wild-type splenocytes (Fig. 1C). This suggested an advantage of wild-type cells expressing polyclonal B cell receptors.

To further confirm that B cell-specific mechanisms are responsible for the bone marrow protective activity in IFRag−/− and IFNAR−/− mice, we adoptively transferred purified wild-type B cells.
cells into groups of Ifrag<sup>-/-</sup> mice and compared their bone marrow responses to animals in which total wild-type splenocytes were transferred or animals in which no cells were transferred (untransferred) over the course of Pneumocystis lung infection. As demonstrated in Fig. 2A, both total-splenocyte-transferred as well as total-splenocyte-transferred plus wild-type B-cell-transferred mice showed significant protection from bone marrow failure as a result of Pneumocystis lung infection, but they promote extramedullary hematopoiesis as evidence for a bone marrow stress response. (A) Total bone marrow cell numbers of uninfected Ifrag<sup>-/-</sup> mice compared to those of Ifrag<sup>-/-</sup> mice infected with Pneumocystis murina on day 16 postinfection that were either left unreconstituted or that had received either total wild-type splenocytes or purified wild-type B cells prior to infection. Five mice per group were assessed. (B) H&E-stained histological sections of formalin-fixed and paraffin-embedded livers and spleens of mice in the groups compared, demonstrating evidence of extramedullary hematopoiesis in the form of cell nests in the liver (marked by an asterisk) and accumulation of megakaryocytes in the spleen (marked by arrows). For statistical analysis of data, a one-way ANOVA was performed followed by a Tukey posthoc test. Values that are significantly different are indicated as follows: *, P < 0.05; **, P < 0.001. Values that are not significantly different (n.s) are also indicated.

FIG 1 B cells protect hematopoiesis during responses to Pneumocystis lung infection by B cell receptor-independent mechanisms. (A) Total bone marrow (BM) cell counts obtained from lymphocyte-deficient Ifrag<sup>-/-</sup> and lymphocyte-competent Ifnar<sup>-/-</sup> mice over a 16-day course of Pneumocystis murina (PC) lung infection. (B) Total bone marrow count from Pneumocystis-infected Ifrag<sup>-/-</sup> mice at day 16 postinfection compared to those Ifrag<sup>-/-</sup> mice in which either splenocytes derived from wild-type (WT) mice, B cell-deficient µMT mice, or splenocytes from mice exclusively expressing a B cell receptor from hen egg lysozyme were adoptively transferred. The results for Ifrag<sup>-/-</sup> mice in which no cells were transferred (untransferred) are also shown. (C) Relative amount of neutrophils expressed as a percentage of total bone marrow cells analyzed by microscopy from the same groups (no reconst., immune system not reconstituted) displayed in panel B. For statistical analysis of the data in panel A, a two-way ANOVA was performed followed by a Bonferroni posthoc test. For statistical analysis of data in panels B and C, a one-way ANOVA was performed followed by a Tukey posthoc test. Values that are significantly different are indicated as follows: ***, P < 0.001; ****, P < 0.0001; ###, P < 0.001 when comparing differences between Ifrag<sup>-/-</sup> and WT spleen versus Ifrag<sup>-/-</sup> and HELµMT spleen.

FIG 2 B cells do not require T cell-mediated help to facilitate protection from bone marrow failure as a result of Pneumocystis lung infection, but they promote extramedullary hematopoiesis as evidence for a bone marrow stress response. (A) Total bone marrow cell numbers of uninfected Ifrag<sup>-/-</sup> mice compared to those of Ifrag<sup>-/-</sup> mice infected with Pneumocystis murina on day 16 postinfection that were either left unreconstituted or that had received either total wild-type splenocytes or purified wild-type B cells prior to infection. Five mice per group were assessed. (B) H&E-stained histological sections of formalin-fixed and paraffin-embedded livers and spleens of mice in the groups compared, demonstrating evidence of extramedullary hematopoiesis in the form of cell nests in the liver (marked by an asterisk) and accumulation of megakaryocytes in the spleen (marked by arrows). For statistical analysis of data, a one-way ANOVA was performed followed by a Tukey posthoc test. Values that are significantly different are indicated as follows: *, P < 0.05; **, P < 0.001; ***, P < 0.0001. Values that are not significantly different (n.s) are also indicated.
as purified-B cell-transferred IFrag−/− mice retained equally high bone marrow cell numbers, while untransferred IFrag−/− mice progressed to bone marrow failure 16 days after *Pneumocystis* lung infection. These experiments confirmed that B cells alone protect bone marrow functions during systemic responses to *Pneumocystis* lung infection, and this protective activity does not require cognate help from CD4+ T cells present in the spleen. However, as previously also observed in lymphocyte-competent IFNAR−/− mice, extramedullary hematopoiesis in both liver and spleen was evident histologically in both transferred groups as a reflection of a continued bone marrow stress response (Fig. 2B) which is not present in either lymphocyte-competent wild-type mice or lymphocyte-deficient RAG−/− mice with intact IFN-α/β (alpha/beta interferon) receptor (IFNAR) expression (50). Interestingly, compensatory extramedullary hematopoiesis could not be detected in untransferred but infected IFrag−/− mice that progressed to bone marrow failure. This either suggested a role of B cells in promoting a beneficial niche environment for hematopoietic cell progenitors/hematopoietic stem cells at extramedullary sites or a role of B cells in neutralizing mechanisms that would otherwise harm circulating hematopoietic stem cell/progenitor functions.

Given the evidence of continued hematopoietic stress, we evaluated whether B cell transfer into IFrag−/− mice was sufficient to maintain robust hematopoietic progenitor activity in bone marrow. Thus, 10^5 bone marrow cells isolated from either B cell-transferred or untransferred IFrag−/− mice at day 16 after *Pneumocystis* infection were plated in a hematopoietic colony-forming assay (CFU assay), and the colony-forming activity of granulocytic progenitor cells was compared to bone marrow cells isolated from uninfected IFrag−/− mice. As demonstrated in Fig. 3B, the bone marrow CFU activity remained robust and was commonly elevated than baseline activity in response to a decrease in CD11b+ Gr-1hi neutrophil numbers as a result of the infection (Fig. 3C). These data suggested that B cell transfer protected hematopoietic progenitor functions despite continued increased cellular turnover and accelerated neutrophil loss.

**Adaptively transferred B cells protect hematopoiesis during the course of *Pneumocystis* lung infection without being retained in bone marrow.** To further gain insight into how B cells protect hematopoiesis during systemic responses to *Pneumocystis* lung infection, we monitored trafficking of transferred B cells in IFrag−/− mice over the course of infection. To do this, two different methodologies were used. We first transferred B cells labeled with a fluorescent membrane dye (Vybrant dye) at day −1 and examined spleen, bone marrow, and lung for accumulation of fluorescently labeled cells using FACS analysis on day 0 (day of infection) and days 1, 3 and 5 postinfection. As demonstrated in Fig. 4A, fluorescently labeled cells could be easily detected in the spleen and lung of B cell-transferred mice on day 0 and day 1, but were less apparent on day 3 postinfection and undetectable on day 5 (data not shown). In contrast, no cells could be convincingly detected in bone marrow post day 0 (day of infection). Using this approach, it was unclear whether cells were quickly undetectable due to a dilution effect of the membrane dye following cell proliferation or whether the cells had died. Thus, we tracked transferred B cells within IFrag−/− mice over the course of *Pneumocystis* lung infection in independent experiments using B cell-specific antibody staining (anti-B220 and anti-IgM) and detection by FACS analysis. Figure 4B shows the gating strategy based on forward/sideward scatter profile and double staining for IgM and B220 in lymphocyte-competent IFNAR−/− mice as a positive control and applied to lymphocyte-deficient IFrag−/− mice prior to transfer in which no IgM+B220+ B cells were detected in any tissue tested. In contrast, IgM+B220+ B cells could be detected in transferred
IFrag−/− mice in spleen, lung, and MLNs on day 3, 7, and 10 postinfection but never convincingly in bone marrow, which was consistent with Vybrant dye tracking experiments.

**B cell-mediated protection from bone marrow failure is associated with induction of immune modulatory cytokines.** Bone marrow failure in I\(\text{Frag}^{-/-}\) mice is associated with increased serum levels for the inflammasome-processed cytokines IL-1β and IL-18, but also for IL-12 and IFN-γ starting between day 7 and 10 postinfection. Importantly, this systemic effect is not observed in RAG−/− mice which lack bone marrow stress (51). To define whether the systemic inflammatory cytokine profile is directly modulated by the transfer of B cells into I\(\text{Frag}^{-/-}\) mice, a comparative analysis of some signature serum cytokines was performed in Pneumocystis-infected untransferred and B cell-transferred I\(\text{Frag}^{-/-}\) mice. As demonstrated in Fig. 5A to C in both untransferred and B cell-transferred mice with Pneumocystis lung infections, serum levels for IL-1β, IL-12, and IFN-γ were clearly elevated in both groups by day 10 postinfection. However, while cytokine levels continued to rise in untransferred I\(\text{Frag}^{-/-}\) mice, inflammatory cytokine levels decreased in B cell-transferred mice by day 16 postinfection.

**B cell-mediated induction of IL-10 and IL-27 contribute to protection of hematopoiesis when type I IFN signaling is absent.** To determine whether B cells provide or induce a regulatory cytokine program in other cell types possibly capable of modulating inflammatory immune activation pathways following their induction, we compared serum levels of IL-10, IL-27 and interleukin 1 receptor antagonist (IL1Ra). As demonstrated in Fig. 6A to C, these cytokines, although also induced in untransferred mice, were significantly higher in B cell-transferred
FIG 5  B cell transfer into Ifrag−/− mice does not significantly change the serum expression profile of proinflammatory mediators associated with induction of bone marrow dysfunctions following Pneumocystis lung infection. (A) Changes of total bone marrow cell numbers in Ifrag−/− mice in which no cells were transferred (untransferred) and Ifrag−/− mice in which B cells were transferred on days 0, 10 and 16 of Pneumocystis lung infection. (B) Comparisons of Pneumocystis lung burdens displayed as nucleus counts in log10 units between untransferred and B cell-transferred Ifrag−/− mice over the 16-day course of infection. (C to E) Serum cytokine concentrations for IL-1β (C), IL-12p70 (D), and IFN-γ (E) found in transferred and B cell-transferred groups over the course of infection displayed in parallel. For statistical analysis of data between the two groups over time in panels A and B, a two-way ANOVA was performed followed by a Bonferroni posthoc test. For statistical analysis of data within one group over time in panels C to E, a one-way ANOVA was performed followed by a Tukey posthoc test. Values that are significantly different are indicated as follows: *, P < 0.05; **, P < 0.01. For panels C to E, the values were compared to the value for day 0.
B Cells Regulate Innate Immunity to Pneumocystis

B. Cells transfer into IFrag−/− mice is associated with increased serum levels for immune regulatory cytokines in response to *Pneumocystis* lung infection. (A to C) Comparative analysis of serum levels for interleukin-10 (A), interleukin-27 (B), and interleukin-1 receptor antagonist (C) in untransferred versus B cell-transfered IFrag−/− mice on day 0, 10, and 16 after *Pneumocystis* lung infection. For statistical analysis of data between the two groups over time, a two-way ANOVA was performed followed by a Bonferroni posthoc test. Values that are significantly different are indicated as follows: *, P < 0.05; ***, P < 0.001; ####, significantly higher in untransferred animals. For panels C to E, the values were compared to the value for day 0.

IFrag−/− mice on day 10 postinfection compared to untransferred IFrag−/− mice.

Thus, to investigate the functional contribution of these potentially regulatory cytokines to B cell-mediated protection of on-demand hematopoiesis, we first compared bone marrow responses of IFrag−/− mice in which B cells derived from either wild-type or IL-10−/− donor mice were transferred to those of untransferred mice following *Pneumocystis* lung infection. As demonstrated in Fig. 7, following an initial drop, total bone marrow count numbers as well as colony-forming activity remained robust in both B cell transfer groups, while these numbers continued to significantly improve hematopoietic progenitor activity for 16 days postinfection as reflected in increased colony-forming activity of bone marrow cells compared to untreated mice, while those mice that had received IL-10 consistently showed greater variability which did not reach statistical significance (Fig. 8C and E).

Thus, to investigate the functional contribution of these potentially regulatory cytokines to B cell-mediated protection of on-demand hematopoiesis, we first compared bone marrow responses of IFrag−/− mice in which B cells derived from either wild-type or IL-10−/− donor mice were transferred to those of untransferred mice following *Pneumocystis* lung infection. As demonstrated in Fig. 7, following an initial drop, total bone marrow count numbers as well as colony-forming activity remained robust in both B cell transfer groups, while these numbers continued to significantly improve hematopoietic progenitor activity for 16 days postinfection as reflected in increased colony-forming activity of bone marrow cells compared to untreated mice, while those mice that had received IL-10 consistently showed greater variability which did not reach statistical significance (Fig. 8C and E).
**DISCUSSION**

B cells are instrumental to the clearance of Pneumocystis lung infection (31, 32, 40, 41, 61). In addition, we were able to implicate B cells as supporters of on-demand hematopoiesis following Pneumocystis lung infection that would otherwise be hampered as the result of systemic immune deviations initiated in the context of a defective type I IFN system. These B cell-mediated mechanisms appeared independent of those required for Pneumocystis clearance (50, 51). This is of interest, as bone marrow dysfunctions resulting in pancytopenia-related comorbidities are common not only in patients with AIDS but also in patients treated for autoimmune diseases. Both patient groups have increased susceptibility to even low-grade Pneumocystis lung infection which might promote deviated systemic innate immune responses that may also hamper hematopoiesis (4, 62–65).

Although Pneumocystis is considered a strictly pulmonary fungal pathogen, rare cases of extrapulmonary manifestations have been reported in humans. This includes three independent cases reported by Rossi and colleagues that demonstrated disseminated Pneumocystosis with bone marrow involvement in patients with malignant lymphoma or HIV infection (66). However, although circulating fungal β-glucan levels can be detected at times early in the course of infection, we have yet been unable to prove dissemination of the pathogen itself to bone marrow of Ifrag−/− mice. Therefore, on the basis of our current and previously published findings, it appears that bone marrow dysfunctions in our model are rather the result of deviated innate functions with profound systemic effects than due to pathogen propagation in bone marrow (50, 51).

Here we set out to define the mechanism by which B cells
B Cells Regulate Innate Immunity to *Pneumocystis*

contribute to the protection of hematopoiesis following *Pneumocystis* lung infection in our model. We found that when B cells are transferred into Ifrag−/− mice, they provide bone marrow protection by mechanisms that maintain hematopoietic progenitor activity which allows the replenishment of depleted cells. They do this independently of their antigen receptor specificity and in a T cell-independent manner. These data suggested that B cells convey their protective effect on bone marrow by mechanisms that require neither formation of an immunological synapsis between B and CD4+ T cells nor secretion of antigen-specific antibodies (67). Cell tracking studies of transferred B cells into Ifrag−/− mice showed no indication of their accumulation in bone marrow but showed that they predominantly home to the spleen and to a lesser degree to the lung and adjacent lymph nodes. These data strongly suggested that B cells may influence the outcome of the systemic inflammatory effects of *Pneumocystis* lung infection by either directly modulating the innate immune pathways initiated in the lung or by providing regulatory functions that interfere downstream of specific inflammatory pathways. Although hematopoiesis is stimulated by inflammatory signals intended to promote cellular maturation and mobilize inflammatory cells to the site of infection (reviewed in references 68 and 69), exuberant inflammatory stimuli can be harmful to hematopoietic stem cell functions in part by the induction of functional senescence as a result of proliferative exhaustion (63, 70). However, the mechanisms that balance these effects on hematopoiesis are still poorly defined, and

**FIG 8** Administration of recombinant IL-10 and IL-27 provide separate and partial protection from bone marrow failure in Ifrag−/− mice. (A) Total bone marrow cell numbers of groups of Ifrag−/− mice on day 10 postinfection that received combined treatment with recombinant IL-10 and IL-27 or received IL-10 or IL-27 alone or were left untreated. All cytokines were administered subcutaneously at a concentration of 400 ng/day for IL-10 and 250 ng/day for IL-27. (B to E) In two separate experiments, individual treatment with either IL-27 (B and C) and IL-10 (D and E) were continued throughout day 16 postinfection, and total bone marrow cell numbers were compared to untreated but infected mice (B and D) and hematopoietic progenitor activity was evaluated in colony assays (C and E). For statistical analysis, all comparisons were made to untreated mice and either a one-way ANOVA followed by a Tukey posthoc test or a Student’s *t* test for pairwise comparisons was performed. Values that are significantly different are indicated as follows: *, *P* < 0.05.
our model demonstrates a critical role of B cells in protecting hematopoiesis during early innate responses to *Pneumocystis* lung infection.

Consistent with this observation, B cells with regulatory, immune suppressive activity (Breg) have been defined within both follicular and marginal zone cell populations (reviewed in references 71 and 72). Breg of follicular origin are regulators of adaptive immunity and facilitate this activity in an antigen-specific and B cell receptor-dependent manner. In contrast, marginal zone B cells act as gatekeepers of innate immunity that modulate maturation and function of innate immune cells, including dendritic cells (DCs), resulting in profound immune suppression. Communication between these “innate-like” B cells and DCs is at least in part facilitated via secretion of IL-10 and CD40-CD40 ligand (CD40L) interaction (73, 74). Although both follicular and marginal zone B cells are capable of producing substantial amounts of IL-10, innate-like B cells are able to produce IL-10 independent of B-cell receptor-mediated stimulation but as the result of innate immune activation (75).

Similarly, type I IFNs can be immune regulatory and promote IL-10 and IL-27 production in innate immune cells such as dendritic cells and suppress inflammasome-mediated immune activation (56, 76–78). This is of interest, as previous work in our model of *Pneumocystis* lung infection-induced bone marrow dysfunctions found that these systemic effects may be due to exuberant Toll-like receptor (TLR) and especially inflammasome-mediated innate immune pathways likely due to the absence of type I IFN-induced immune regulation (51, 52). Surprisingly, we found that B cell transfer into IFrag−/− mice did not change the profile of the indicator serum cytokines IL-12, IL-18, and IFN-γ following *Pneumocystis* lung infection compared to untransferred mice. However, serum IL-10 levels in conjunction with IL-27 and IL-1 receptor antagonist (IL1Ra) were significantly higher in B cell-transferred IFrag−/− mice compared to untransferred mice. B cells can produce IL-10; however, IL-27 and IL1Ra are primarily monocyctic/dendritic cell-derived mediators with immune modulatory activity. Specifically, IL-27 functions as an upstream regulator of IL-10 production in innate and adaptive immune cells, while IL1Ra is IL-10-induced and modulates IL-1-mediated activity (79–82). This suggested a modulatory role of B cells on DC/macrophage responses in our system.

Work by other investigators had already demonstrated an immune modulatory role of IL-10 on pulmonary response to *Pneumocystis* infection. Qureshi et al. have shown that IL-10−/− mice demonstrate enhanced clearance kinetics in CD4+ T cell–dependent mice but increased lung damage in CD4+ T cell–depleted models (83). Furthermore, Ruan et al. have demonstrated that local delivery of viral IL-10 in a gene therapy-like approach in a mouse model is able to suppress the pulmonary damage caused by the hyperinflammatory response that commonly follows immune reconstitution as the result of low-grade *Pneumocystis* lung infection (84). Thus, we first evaluated to what extent B cell–derived IL-10 contributes to protection from bone marrow failure in our system by comparing the efficiency of B cells unable to produce IL-10 (IL-10−/− B cells) to those of wild-type B cells to protect from bone marrow failure when transferred into IFrag−/− mice. While we were surprised to see that B cells transferred from IL-10−/− mice were as capable of maintaining hematopoietic progenitor activity in bone marrow as wild-type B cells over the course of *Pneumocystis* lung infection, the number of mature neutrophils was clearly reduced compared to wild-type B cell–transferred mice on day 16 postinfection. This suggested that IL-10 may be important in protection from mechanisms that accelerate increased cellular turnover of maturing bone marrow cells but that it is irrelevant for protection of progenitor functions. Although this observation is consistent with our impression of a two-pronged mechanism in the pathogenesis of bone marrow failure in our model (51), serum cytokine analysis revealed that IL-10 serum levels of IL-10−/− B cell–transferred mice were still above those of untransferred mice and nearly as high as those from mice in which wild-type B cells were transferred. Thus, transferred B cells may indeed modulate the functions of innate immune cells in lung and spleen to also promote regulatory dendritic cells or macrophages capable of producing IL-10 and other innate immune regulators (reviewed in references 85 and 86). In support of this, we found in preliminary experiments that co-culture of B cells with pulmonary CD11b+ MHC+ CD11c+ or CD11c− cells (macrophage/DCs) isolated from IFNAR-deficient mice on day 10 after *Pneumocystis* lung infection greatly enhanced secretion of the immune modulatory cytokine IL-27 following phorbol ester stimulation compared to cultures from pulmonary CD11b+ CD11c+ or CD11c− macrophage/DCs alone (data not shown).

Because IL-27 is both directly immune modulatory and is also an upstream regulator of IL-10 (56, 60, 89), we next treated IFrag−/− mice with IL-10 and IL-27 either alone or combined over the course of *Pneumocystis* lung infection to evaluate the outcome on bone marrow failure in our model. These experiments revealed that IL-10 and to a lesser degree IL-27 ameliorated the loss of mature bone marrow cells normally visible on day 10 postinfection, and IL-27 was particularly capable of improving progenitor activity for 16 days postinfection. While these treatments were not as effective as B cell transfer itself, it did support a role for both cytokines in the bone marrow protective ability of B cells. One aspect likely contributing to decreased efficiency of the cytokine treatments may be the inability to maintain continuous cytokine levels sufficient to convey optimal protection. Furthermore, additional factors not yet defined and/or tested may amplify the B cell–mediated effects. Given that we predict a significant role of exuberant inflammasome-mediated immune effects to be at least partially responsible for the observed systemic complications in our model, the increased serum levels of IL1Ra seen following B cell transfer may also play a significant role in the B cell–mediated protective effects. Preliminary experiments using daily administration of a lower dose of human recombinant IL1Ra (Kineraet, 25 mg/kg/day) (55) have not resulted in satisfactory effects, and serum levels of the human recombinant protein were barely detectable. Therefore, we will continue to evaluate this pathway using increasing dosages and combined treatments with other immune modulators to clearly define the role of IL1Ra in modulating the extent of bone marrow dysfunctions following *Pneumocystis* lung infection in our model. An additional candidate highly produced by B cells and not yet pursued is the immune modulator osteoprotegrin. Osteoprotegrin acts as a decoy receptor for the proapoptotic factor TRAIL (TNF-related apoptosis-inducing ligand) as well as the osteoclast differentiation factor RANKL (receptor activator of NF-κB ligand) (90, 91). Both TRAIL and RANKL are uniquely upregulated in the bone marrow of both lymphocyte-
competent and -deficient IFNAR-deficient mouse strains compared to IFNAR-intact mice and as the result of Pneumocystis lung infection. We know that an imbalance between these players does exist at least in Ifnar−/− mice (92).

In conclusion, we were able to define a new and expanded role of B cells in modulating the outcome of innate immune responses to the strictly pulmonary pathogen Pneumocystis which can otherwise have profound systemic effects. Findings with our mouse model may reflect scenarios relevant to humans under conditions when the type I IFNs can be suppressed and therefore promote inflammasome-mediated immune activation (51). In addition to when the type I IFNs can be suppressed and therefore promote apoptosis in a variety of immune cells, including B cells (97). Type I IFN responses and B cell functions also decline during aging (98–101), resulting in a latent stage of immune suppression and susceptibility to even low-grade Pneumocystis infection (102). Under any of these conditions, systemic inflammation is common, and bone marrow dysfunctions are reported often without a clear pathogenic link (63, 64, 103–110).

While Pneumocystis lung infection is certainly not the main driver of all bone marrow dysfunctions, our model exemplifies the interconnectivity of organ systems during inflammation and the expanded role that Pneumocystis may play, not only as a pulmonary opportunistic pathogen but also as a trigger of significant systemic comorbidities. This work stresses the critical role that type I IFNs play in modulating local responses to this ubiquitous, often underappreciated, pathogen and the broader functions that B cells have in promoting successful immune responses during Pneumocystis infection. They do this by also regulating induction of early innate immune pathways independent from their role in pathogen clearance.

ACKNOWLEDGMENTS

This work was supported by the following funding sources: NIH RO1 HL90488 and COBRE 2P20RR020185.

We thank A. G. Harmsen for generously providing us with HEL4MT mice that he had previously received from Francis Lund. We declare that we have no conflicts of interest.

REFERENCES


iai.asm.org 755

February 2015 Volume 83 Number 2 Infection and Immunity


46. Theus SA, Smulian AG, Steele P, Linke MJ, Walzer PD. 1998. Immune-
74. Agarwal A. 2013. Mechanisms and implications of age-associated im-


